证券代码：301301 证券简称：川宁生物 公告编号：2024-039 伊犁川宁生物技术股份有限公司 关于全资子公司参与投资产业基金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、投资标的：上海临港大零号湾启创生科私募投资基金合伙企业（有限合 伙）（以下简称"合伙企业"）。 2、投资金额：伊犁川宁生物技术股份有限公司（以下简称"公司"）全资 子公司伊犁川宁投资发展有限公司（以下简称"川宁投资"）拟作为有限合伙人 （LP）使用自有资金认缴出资人民币 6,000 万元参与投资合伙企业。 3、风险提示：合伙企业设立后需按照有关监管要求完成基金备案等必要手 续，存在不能满足设立条件而无法登记备案成功的风险；因投资标的具有周期长、 流动性较低的特点，本次投资存在回收期较长，在投资过程中可能受到宏观经济、 行业周期、监管政策、被投企业自身经营管理等多种因素影响，可能存在投资后 无法实现预期收益的风险；公司作为有限合伙人参与设立合伙企业，但不参与合 伙企业合伙事务的具体管理，对合伙企业的日常经营不具有控制权或可施加重大 影响。 一、对外投资概述 ...

证券代码：301301 证券简称：川宁生物 伊犁川宁生物技术股份有限公司投资者关系活动记录表 编号：0013 | --- | --- | --- | |-------------------------|------------------------------|------------------------------------------------------| | | | | | | ☐ 特定对象调研 | ☐ 分析师会议 | | | ☐ 媒体采访 | ☐ 业绩说明会 | | 投资者关系 | ☐ 新闻发布会 | 路演活动 | | 活动类别 | ☐ 现场参观 | ☐业绩交流会 | | | ☐ 其他：电话调研 | | | 参与单位名称 及人员姓名 | 机构、媒体及公众投资者 | 中信证券、中信建投、山西证券、东方证券、华安证券等 | | 时间 | 年 月 | 日（周五）下午 | | 地点 | 2024 9 20 深圳证券交易所 8 | 14:00~17:00 楼上市大厅 | | | | | | 上市公司接待 人员姓名 | 副总经理、董事会秘书顾祥先生 | | | | | | | | 1. 略总体是什么 ...

一、路演活动安排 4、参会人员：公司副总经理、董事会秘书顾祥先生 证券代码：301301 证券简称：川宁生物 公告编号：2024-038 伊犁川宁生物技术股份有限公司 关于参加医药生物行业上市公司 2024年度集中路演活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步展现公司经营发展情况，加强与广大投资者的互动交流，促进提升 公司质量和投资价值，伊犁川宁生物技术股份有限公司（以下简称"公司"）将 参加在深圳证券交易所上市大厅举办的医药生物行业上市公司 2024 年度集中路 演活动，现将相关事项公告如下： 伊犁川宁生物技术股份有限公司董事会 2024 年 9 月 17 日 二、投资者参与方式 1、本次路演活动将通过深圳证券交易所提供的"互动易"平台举行，投资 者 可 于 2024 年 9 月 20 日 下 午 14:00-17:00 登录" 互 动 易 "网站 （http://irm.cninfo.com.cn），进入"云访谈"栏目，在线参与本次路演活动，也 可扫描下方二维码观看直播及参与交流。 1、活动主题：医药生物新机遇 2、活动时间：20 ...

Investment Rating - The investment rating for the company is "Buy - A" with a target price of 12.73 CNY for the next six months [6][9]. Core Views - The company has demonstrated sustained high growth in its performance, with a significant increase in revenue and net profit driven by strong market demand for antibiotics and ongoing process optimization [2][4]. - The company is actively advancing its synthetic biology projects, with several products already in various stages of production and commercialization [5]. Financial Performance - In H1 2024, the company achieved a revenue of 3.195 billion CNY, representing a year-on-year growth of 32.20%. The net profit attributable to shareholders was 766 million CNY, up 96.05% year-on-year [2]. - The Q2 2024 gross margin was 36.13%, an increase of 5.25 percentage points year-on-year, while the net profit margin reached 24.74%, up 5.97 percentage points year-on-year [3]. Product Segmentation - The revenue breakdown for H1 2024 shows that the main products include thiocyanate red mycin (29.15%), cephalosporin intermediates (23.48%), and penicillin intermediates (40.72%) [2]. Cost Management - The company has effectively optimized its production processes, leading to increased output and reduced costs, which has positively impacted profit margins [4]. Synthetic Biology Projects - The company has a rich pipeline of synthetic biology projects, with products like red myrtenol and 5-hydroxytryptophan already in production stages, indicating a strong potential for future revenue growth [5]. Future Projections - Revenue growth is projected at 24.3%, 13.0%, and 7.9% for 2024 to 2026, respectively, with net profit growth expected at 50.4%, 20.3%, and 13.1% during the same period [9][10].

证券代码：301301 证券简称：川宁生物 伊犁川宁生物技术股份有限公司投资者关系活动记录表 编号：0012 | --- | --- | --- | --- | --- | --- | --- | |-------------------------|----------------------------------------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Investment Rating - The report maintains a "Recommended" rating for the company [2]. Core Insights - The company achieved a revenue of 3.195 billion yuan in the first half of 2024, representing a year-on-year growth of 32.20%, and a net profit attributable to shareholders of 766 million yuan, which is a 96.05% increase year-on-year [2]. - The growth in performance is attributed to the increase in both volume and price of core products, driven by downstream demand, with specific products showing significant revenue increases [2]. - The company has successfully reduced costs and improved efficiency, leading to a notable increase in profit margins, with a gross profit margin of 35.31% and a net profit margin of 23.98% in the first half of 2024 [2]. - Continuous innovation in research and development has led to several products entering trial production, indicating a strong pipeline for future growth [2]. Financial Summary - The company forecasts net profits of 1.414 billion yuan, 1.691 billion yuan, and 1.956 billion yuan for 2024, 2025, and 2026 respectively, with year-on-year growth rates of 50.36%, 19.55%, and 15.66% [3]. - Revenue projections for the next three years are 5.780 billion yuan, 6.512 billion yuan, and 7.186 billion yuan, with growth rates of 19.84%, 12.65%, and 10.35% respectively [3]. - The company’s gross margin is expected to improve from 34.64% in 2024 to 37.89% in 2026, reflecting ongoing operational efficiencies [3].

Investment Rating - The report maintains a "Recommended" rating for the company [2][3] Core Views - The company achieved a revenue of 3.2 billion yuan in H1 2024, representing a year-on-year growth of 32.2%, and a net profit of 770 million yuan, up 96.1% year-on-year [2] - The antibiotic intermediate sector is experiencing a competitive landscape optimization, with product prices expected to remain high due to increasing demand and limited supply [2] - The company is expanding its synthetic biology capabilities, with several products in various stages of development, which could become a significant growth driver [2] Financial Forecasts - Revenue projections for 2024-2026 are 6.07 billion, 6.91 billion, and 7.77 billion yuan, with year-on-year growth rates of 25.9%, 13.8%, and 12.5% respectively [3][6] - Net profit forecasts for the same period are 1.46 billion, 1.75 billion, and 2.13 billion yuan, with growth rates of 55.2%, 20.0%, and 21.8% respectively [3][6] - The projected PE ratios for 2024-2026 are 17, 14, and 11 [3][6]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported strong performance in H1 2024, with revenue of 3.195 billion yuan (+32.20% YoY) and net profit attributable to shareholders of 766 million yuan (+96.05 YoY), slightly exceeding expectations [3] - The company has experienced six consecutive quarters of high growth, driven by strong demand for antibiotics post-public health events and rising raw material prices, benefiting from its position as an industry leader [3] - The synthetic biology segment has a rich R&D pipeline, with several projects expected to contribute profits in the near term, supported by a new production base in Shanghai [3][4] Financial Performance and Forecast - Revenue forecast for 2024-2026 has been adjusted, with net profit estimates raised from 1.1 billion, 1.21 billion, and 1.38 billion yuan to 1.5 billion, 1.82 billion, and 2.05 billion yuan respectively, corresponding to P/E ratios of 19, 16, and 14 times [4] - The company is expected to maintain high growth due to rising product prices and successful advancements in synthetic biology projects [4] - The company achieved a net profit margin of 19.50% in 2023, projected to increase to 24.52% in 2024 [9] Market Data - The closing price of the stock is 10.91 yuan, with a market capitalization of 24.298 billion yuan [6] - The company has a P/E ratio of 30.38 based on the latest diluted earnings per share [10] Operational Highlights - The company’s synthetic biology research institute has developed multiple projects, with some expected to be operational soon, leveraging resource advantages in Xinjiang and Central Asia [3] - The new production base is designed to have flexible production capabilities for various high-value products, which is anticipated to drive continued revenue growth [3]

长江证券承销保荐有限公司 关于伊犁川宁生物技术股份有限公司 2024 年半年度持续督导跟踪报告 1 | 5.现场检查情况 | | | --- | --- | | （1）现场检查次数 | 1 | | （2）现场检查报告是否按照本所规定报送 | 是 | | （3）现场检查发现的主要问题及整改情况 | 不适用 | | 6.发表独立意见情况 | | | （1）发表独立意见次数 | 5 | | （2）发表非同意意见所涉问题及结论意见 | 不适用 | | 7.向本所报告情况（现场检查报告除外） | | | （1）向本所报告的次数 | 无 | | （2）报告事项的主要内容 | 不适用 | | （3）报告事项的进展或者整改情况 | 不适用 | | 8．关注职责的履行情况 | | | （1）是否存在需要关注的事项 | 否 | | （2）关注事项的主要内容 | 不适用 | | （3）关注事项的进展或者整改情况 | 不适用 | | 9.保荐业务工作底稿记录、保管是否合规 | 是 | | 10.对上市公司培训情况 | | | （1）培训次数 | 1 次 | | （2）培训日期 | 2024 年 7 月 11 日 | | （3）培训的 ...

长江证券承销保荐有限公司 关于伊犁川宁生物技术股份有限公司 2024 年度持续督导定期现场检查报告 | 保荐机构名称：长江证券承销保荐有限公司 被保荐公司简称：川宁生物（301301） | | --- | | 保荐代表人姓名：李振东 联系电话：010-57065264 | | 保荐代表人姓名：杨光远 联系电话：021-61118978 | | 现场检查人员姓名：杨光远 | | 现场检查对应期间：2023 年 7 月至 2024 年 6 月 | | 至 至 现场检查时间：2024.7.8 2024.7.12，2024.8.15 2024.8.16 | | 一、现场检查事项 现场检查意见 | | （一）公司治理 是 否 不适用 | | 现场检查手段：（1）查阅公司章程及各项规章制度；（2）查阅"三会"文件，包括会议通 知、签到表、会议决议、会议记录、公告等；（3）实地查看公司主要生产经营场所，了解 | | 公司治理及独立性情况；（5）访谈公司相关人员，了解公司基本制度的执行情况，了解公 | | 司董事、监事和高级管理人员履行职务勤勉尽责情况及变动情况，了解控股股东、实际控制 | | 人遵守相关承诺的情况。 | | ...